Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae
- PMID: 335003
- DOI: 10.1093/infdis/136.5.693
Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae
Abstract
The inhibition of the activity of enterotoxins by bismuth salts was assessed in laboratory models. In the Y-1 adrenal cell tissue culture system, a commercial preparation containing bismuth subsalicylate reduced the activity of crude toxin from Vibrio cholerae by 10(4)-fold as compared with the activity of controls. Similar results were obtained with use of the adult rabbit ligated intestinal loop model. The preparation failed to affect crude Escherichia coli or cholera toxin activity once these toxins had become bound to intestinal mucosa. Pretreatment of ligated loops with the preparation reduced the fluid accumulation mediated by crude E. coli and cholera toxins by 78% and 91%, respectively. Bismuth subsalicylate and the complex vehicle of the preparation also inactivated toxin; however, bismuth subsalicylate was more effective when combined with the vehicle. Bismuth subcarbonate failed to inhibit fluid accumulation in ligated loops. Preparations containing bismuth subsalicylate may be effective in the prevention of diarrhea mediated by toxigenic E. coli.
Similar articles
-
Antisecretory and antiinflammatory properties of bismuth subsalicylate.Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S16-20. doi: 10.1093/clinids/12.supplement_1.s16. Rev Infect Dis. 1990. PMID: 2305173
-
Evaluation of BW942C, a novel antidiarrheal agent, against enterotoxins of Escherichia coli and Vibrio cholerae.Infect Immun. 1985 Jun;48(3):754-8. doi: 10.1128/iai.48.3.754-758.1985. Infect Immun. 1985. PMID: 3838969 Free PMC article.
-
Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins.Infect Immun. 1982 Feb;35(2):471-5. doi: 10.1128/iai.35.2.471-475.1982. Infect Immun. 1982. PMID: 7035365 Free PMC article.
-
Mechanism of action of cholera toxin & other toxins.Indian J Med Res. 1996 Jul;104:28-37. Indian J Med Res. 1996. PMID: 8783505 Review.
-
Pharmacology of bismuth-containing compounds.Rev Infect Dis. 1991 Jul-Aug;13 Suppl 8:S691-5. doi: 10.1093/clinids/13.supplement_8.s691. Rev Infect Dis. 1991. PMID: 1925310 Review.
Cited by
-
Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera.Pathog Glob Health. 2015 Sep;109(6):275-82. doi: 10.1179/2047773215Y.0000000028. Epub 2015 Aug 11. Pathog Glob Health. 2015. PMID: 26260354 Free PMC article. Clinical Trial.
-
Travellers' diarrhoea: contemporary approaches to therapy and prevention.Drugs. 2006;66(3):303-14. doi: 10.2165/00003495-200666030-00003. Drugs. 2006. PMID: 16526819 Review.
-
Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea.Dig Dis Sci. 2021 Jul;66(7):2323-2335. doi: 10.1007/s10620-020-06509-7. Epub 2020 Aug 8. Dig Dis Sci. 2021. PMID: 32772204 Free PMC article.
-
Bismuth salicylate for diarrhea in children.Can Fam Physician. 2013 Aug;59(8):843-4. Can Fam Physician. 2013. PMID: 23946025 Free PMC article.
-
Intestinal epithelial function: the case for immunophysiological regulation. Implications for disease (2).Dig Dis Sci. 1993 Sep;38(9):1735-45. doi: 10.1007/BF01303185. Dig Dis Sci. 1993. PMID: 8359088 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials